# MMAE

Source: https://onco.cc/terms/mmae/  
OnCo record `mmae` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MMAE is the tubulin-blocking payload in brentuximab, enfortumab, polatuzumab and tisotumab vedotin, four approved ADCs: it halts cell division and, being membrane permeable, leaks into neighbouring tumour cells. Nerve damage and low neutrophil counts are its signature side effects.

## Summary

Monomethyl auristatin E is a synthetic analogue of dolastatin 10 that binds tubulin and halts mitosis. Released by cleavable linkers (typically valine-citrulline), it is membrane permeable, giving a strong bystander effect. It is a substrate for P-glycoprotein, which drives resistance. Peripheral neuropathy and neutropenia are class effects seen with brentuximab vedotin, enfortumab vedotin, polatuzumab vedotin and tisotumab vedotin.

## Fields

- Kind: Term
- Last checked: 2026-09-09
- Also known as: monomethyl auristatin E; vedotin payload; monomethyl auristatin E, vedotin

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Monomethyl_auristatin_E
- Wikipedia: https://en.wikipedia.org/wiki/Monomethyl_auristatin_E

## Connected records

- terms: [Bystander effect (ADC)](https://onco.cc/terms/bystander-effect/), [Drug efflux pumps (ABC transporters)](https://onco.cc/terms/efflux-pump/), [mc-Val-Cit-PABC](https://onco.cc/terms/mc-vc-pabc/), [Payload (ADC)](https://onco.cc/terms/payload/), [Tubulin inhibitor payloads](https://onco.cc/terms/tubulin-inhibitor-payloads/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/), [Disitamab vedotin](https://onco.cc/drugs/disitamab-vedotin/), [Enfortumab vedotin](https://onco.cc/drugs/enfortumab-vedotin/), [Sonesitatug vedotin](https://onco.cc/drugs/cmg901/), [Telisotuzumab vedotin](https://onco.cc/drugs/telisotuzumab-vedotin/), [Tisotumab vedotin](https://onco.cc/drugs/tisotumab-vedotin/), [Zilovertamab vedotin](https://onco.cc/drugs/zilovertamab-vedotin/)
- pathways: [Drug efflux pumps (ABC transporters)](https://onco.cc/pathways/drug-efflux-pumps/), [Mitosis & the spindle assembly checkpoint](https://onco.cc/pathways/mitotic-spindle-checkpoint/)

---
JSON: https://onco.cc/api/v1/entities/mmae.json